If approved, crovalimab would be the first monthly subcutaneous treatment for patients with PNH, with the option to self-administer outside of a supervised healthcare setting.
Tag Archive for: Genentech
Roche’s Genentech on Thursday released early-stage data on its KRAS inhibitor, divarasib, as it hopes to join Amgen and Mirati in the potential blockbuster cancer market.
Data from the OCARINA II trial shows that a 10-minute subcutaneous injection of Ocrevus achieves similar pharmacokinetics as the typical hours-long intravenous infusion in multiple sclerosis patients.
The entry of biosimilars promotes healthy market competition. It can reduce the prices of branded biologic medicines, according to a new study from the University of Southern California’s Leonard D. Schaeffer Center for Health Policy & Economics.
Regeneron Pharmaceuticals Inc.’s first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company’s shares more than 5% lower in early trade.
Just over a year since Genentech and parent Roche gained approval for Vabysmo, an injectable ophthalmic medicine to treat wet age-related macular degeneration and diabetic macular edema, the companies have launched the first DTC ad for the product.
Polivy is approved for front-line DLBCL as part of a combination regimen including Rituxan, cyclophosphamide, doxorubicin and prednisone.
The combination treatment of AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) met its primary endpoint in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to an interim analysis of the study released Wednesday.
An independent panel of advisers voted to approve Genentech’s Polivy after internal FDA staff raised concerns regarding the efficacy and risk-benefit profile as a first-line treatment for large B-cell lymphoma.
FDA advisers raised concerns regarding the efficacy and risk-benefit profile of Genentech’s Polivy as a first-line treatment for large B-cell lymphoma ahead of a March 9 advisory committee meeting.
